Skip to main content
. 2020 Oct 27;9(1):1832348. doi: 10.1080/2162402X.2020.1832348

Table 5.

Association between baseline plasma ICs levels and number of metastatic sites, localization of metastasis and IMDC Prognostic Risk Group

  Total pts
(n.)		 No. of metastatic sites
 Site of metastasis
 IMDC Prognostic Risk Group
≤2 ≥3 p value* Lung Others p value* Favorable Intermediate p value*
PD-1 (ng/ml)
≤2.11
>2.11
13
8
4
0
9
8
ns
5
1
8
7
ns
4
2
9
6
ns
PD-L1 (ng/ml)
≤0.66
>0.66
10
11
4
0
6
11
0.03
6
0
4
11
0.003
6
0
4
11
0.003
sBTN2A1(ng/ml)
≤6.01
>6.01
3
18
3
1
0
17
0.003
3
3
0
15
0.01
2
4
1
14
ns
sBTN3A1(ng/ml)
≤6.84
>6.84
11
10
4
0
7
10
ns
4
2
7
8
ns
5
1
6
9
ns

* Fisher’s exact test